Intellia Therapeutics (NTLA)
NASDAQ:NTLA

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

1,818 Followers
See the Price Targets and Ratings of:

NTLA Analyst Ratings

Moderate Buy
19Ratings
15 Buy
3 Hold
1 Sell
Based on 19 analysts giving stock ratings to
Intellia
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NTLA Stock 12 Months Forecast

Average Price Target

$102.24
▲(112.12% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $102.24 with a high forecast of $163.00 and a low forecast of $50.00. The average price target represents a 112.12% change from the last price of $48.20.
Highest Price Target$163.00Average Price Target$102.24Lowest Price Target$50.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Credit Suisse
$109.00
Buy
126.14%
Upside
Reiterated
Credit Suisse Maintains Outperform on Intellia Therapeutics, Raises Price Target to $109
RBC Capital
$140.00
Buy
190.46%
Upside
Reiterated
Intellia Therapeutics (NTLA) PT Lowered to $140 at RBC CapitalRBC Capital analyst Luca Issi lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $140.00 (from $150.00) while maintaining a Outperform rating.
Wedbush
$53.00
Hold
9.96%
Upside
Reiterated
Intellia Therapeutics (NTLA) PT Lowered to $53 at WedbushWedbush analyst David Nierengarten lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $53.00 (from $58.00) while maintaining a Neutral rating.
Morgan Stanley
$83.00
Buy
72.20%
Upside
Reiterated
Morgan Stanley Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $83
Brookline Capital Markets
$91.00
Buy
88.80%
Upside
Reiterated
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Quest Diagnostics (NYSE: DGX) and Intellia Therapeutics (NASDAQ: NTLA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

NTLA Financial Forecast

NTLA Earnings Forecast
Next quarter’s earnings estimate for NTLA is -$1.37 with a range of -$1.70 to -$0.21. The previous quarter’s EPS was -$1.49. NTLA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.49% of the time in the same period. In the last calendar year NTLA has Underperformed its overall industry.
Next quarter’s earnings estimate for NTLA is -$1.37 with a range of -$1.70 to -$0.21. The previous quarter’s EPS was -$1.49. NTLA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.49% of the time in the same period. In the last calendar year NTLA has Underperformed its overall industry.
NTLA Sales Forecast
Next quarter’s sales forecast for NTLA is $11.48M with a range of $0.00 to $17.80M. The previous quarter’s sales results were $13.27M. NTLA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year NTLA has Outperformed its overall industry.
Next quarter’s sales forecast for NTLA is $11.48M with a range of $0.00 to $17.80M. The previous quarter’s sales results were $13.27M. NTLA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year NTLA has Outperformed its overall industry.
NTLA Analyst Recommendation Trends
In the current month, NTLA has received 13 Buy ratings 3 Hold ratings, and 0 Sell ratings. The NTLA average analyst price target in the past 3 months is $102.24
In the current month, NTLA has received 13 Buy ratings 3 Hold ratings, and 0 Sell ratings. The NTLA average analyst price target in the past 3 months is $102.24

NTLA Stock Forecast FAQ

What is NTLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is $102.24.
    What is NTLA’s upside potential, based on the analysts’ average price target?
    Intellia Therapeutics has 112.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NTLA a Buy, Sell or Hold?
          Intellia Therapeutics has a conensus rating of Moderate Buy which is based on 15 buy ratings, 3 hold ratings and 1 sell ratings.
            What is Intellia Therapeutics’s price target?
            The average price target for Intellia Therapeutics is $102.24. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $163.00 ,the lowest forecast is $50.00. The average price target represents 112.12% Increase from the current price of $48.2.
              What do analysts say about Intellia Therapeutics?
              Intellia Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis